Clinical Trials Sponsored by S-Evans Biosciences Co.,Ltd.

Total 286 results

Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Heterozygous Familial Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW031 in PMO Subjects

Osteoporosis, Postmenopausal

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (MW032)

Bone Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..

Hyperlipemia

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

COVID-19; and High Infection Risk of SARS-CoV-2

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects

Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer

Breast Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Lymphoma | Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects

Migraine

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

China
Suzhou Neologics Bioscience Co., Ltd.

Not yet recruiting

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects

Pulmonary Fibrosis | Tumor

Australia
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

6MW3511 in Patients With Advanced Solid Tumor

Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

Lymphoma
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Advanced Clear Cell Renal Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Gastric or Esophagogastric Junction Adenocarcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Clinical Study of JS007 in Patients With Advanced Solid Tumors

Patients With Advanced Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Advanced Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19

Covid19

China
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Melanoma | Breast Cancer | Lung Cance

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Asthma | Atopic Dermatitis | COPD

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma (JS001)

Metastatic Melanoma | Unresectable Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

Advanced Hepatocellular Carcinoma (HCC)

China, Singapore
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC

Stage II-III Non-small Cell Lung Cancer

China

3

Subscribe